Skip to main content
main-content

EULAR 2022 Congress

News and expert insight from the 2022 European Congress of Rheumatology | June 1 – 4

EULAR 2022 Congress highlights

Close up of subcutaneous injection into stomach

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

Covid-19 vaccine vial and needle

04-06-2022 | EULAR 2022 | Conference coverage | News

Support for pausing methotrexate only after second COVID-19 vaccine dose

Pausing methotrexate only after the second dose of a COVID-19 vaccine may provide the best balance between antibody response and risk for flare, findings from two randomized controlled trials suggest.

Vector illustration of two profiles with speech bubbles inside their heads - debate concept

03-06-2022 | EULAR 2022 | Conference coverage | News

​​​​​​​The EULAR 2022 Debate: Will COVID-19 have a long-term impact on rheumatology practice?

At the EULAR 2022 Congress in Copenhagen, Denmark, two experts debated whether COVID-19 will have a lasting effect on rheumatology clinical practice.

Seesaw with red and black balls, red wins

03-06-2022 | EULAR 2022 | Conference coverage | News

Chronic, low-dose glucocorticoid benefits outweigh harms in senior patients with RA

Findings from the GLORIA trial suggest that older patients with established rheumatoid arthritis could benefit from 2 years of low-dose glucocorticoids in addition to their existing disease-modifying treatment with a favorable balance of benefit and harm.

X-ray lumbo-sacral spine and pelvis and

01-06-2022 | EULAR 2022 | Conference coverage | News

BE MOBILE trials support bimekizumab for the treatment of axSpA

The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.

Man taking a pill (symbolic image with model)

01-06-2022 | EULAR 2022 | Conference coverage | News

SELECT-AXIS 2: Upadacitinib shows promise for axSpA

Findings from the SELECT-AXIS 2 trial provide further support for the benefits of upadacitinib across the spectrum of axial spondyloarthritis.

Expert video interviews from the EULAR 2022 Congress

Fabian Proft

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

Philippe Carron

15-06-2022 | EULAR 2022 | Conference coverage | Video

BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.

Désirée van der Heijde

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis.

Joseph Merola

07-06-2022 | EULAR 2022 | Conference coverage | Video

The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.

Latest news from the EULAR 2022 Congress

08-06-2022 | EULAR 2022 | Conference coverage | News

Maternal, fetal morbidity rates remain high in SLE

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox


Medicine Matters conference coverage is brought to you in partnership with medwireNews